NDC Package 60492-0249-2 Anthrasil

Anthrax Immune Globulin (human) Liquid Intravenous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
60492-0249-2
Package Description:
7 VIAL in 1 CARTON / 35 mL in 1 VIAL (60492-0249-1)
Product Code:
Proprietary Name:
Anthrasil
Non-Proprietary Name:
Anthrax Immune Globulin (human)
Substance Name:
Anthrax Immune Globulin Human
Usage Information:
ANTHRASIL is an Anthrax Immune Globulin Intravenous (Human) indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. The effectiveness of ANTHRASIL is based solely on efficacy studies conducted in animal models of inhalational anthrax [See 13.2 Animal Toxicology and/or Pharmacology].Limitations:•ANTHRASIL does not have direct antibacterial activity.•ANTHRASIL does not cross the blood-brain barrier and does not prevent or treat meningitis.•There have been no studies of ANTHRASIL in the pediatric, geriatric, or obese populations.
11-Digit NDC Billing Format:
60492024902
NDC to RxNorm Crosswalk:
  • RxCUI: 1722406 - Anthrax immune globulin, human 60 UNT Injection
  • RxCUI: 1722406 - anthrax immune globulin, human 60 UNT Injection
  • RxCUI: 1722407 - Anthrasil 60 UNT Injection
  • RxCUI: 1722407 - anthrax immune globulin, human 60 UNT Injection [Anthrasil]
  • Product Type:
    Plasma Derivative
    Labeler Name:
    Emergent Biosolutions Canada Inc.
    Dosage Form:
    Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
    Administration Route(s):
  • Intravenous - Administration within or into a vein or veins.
  • Sample Package:
    No
    FDA Application Number:
    BLA125562
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    10-05-2015
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 60492-0249-2?

    The NDC Packaged Code 60492-0249-2 is assigned to a package of 7 vial in 1 carton / 35 ml in 1 vial (60492-0249-1) of Anthrasil, a plasma derivative labeled by Emergent Biosolutions Canada Inc.. The product's dosage form is liquid and is administered via intravenous form.

    Is NDC 60492-0249 included in the NDC Directory?

    Yes, Anthrasil with product code 60492-0249 is active and included in the NDC Directory. The product was first marketed by Emergent Biosolutions Canada Inc. on October 05, 2015 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 60492-0249-2?

    The 11-digit format is 60492024902. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-4-160492-0249-25-4-260492-0249-02